Generic Antiretrovirals and the Uncertain Future of HIV Care in the United States
Authors: Renslow Sherer
Journal: Annals of Internal Medicine (2013)

Editorials15 January 2013Generic Antiretrovirals and the Uncertain Future of HIV Care in the United StatesRenslow Sherer, MDRenslow Sherer, MDFrom University of Chicago, Chicago, Illinois.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-158-2-201301150-00010 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Generic antiretroviral drugs have contributed to remarkable achievements in the global HIV epidemic. Mortality has decreased by 24% since 2005, new HIV infections have decreased by 20% since 2001, and 8 million persons are receiving treatment (1). In the United States, 10 available generic antiretrovirals have been used infrequently because of greater toxicity and inferior efficacy. However, when generic efavirenz becomes available in 2013, a regimen of generic efavirenz and lamivudine with branded tenofovir will become a credible alternative to branded regimens.In this issue, Walensky and colleagues (2) mathematically model the effect of the substitution of generic efavirenz and ...References1. Joint United Nations Programme on HIV/AIDS. Global Report: UNAIDS Report on the Global AIDS Epidemic 2012. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2012. Accessed at www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_en.pdf on 12 November 2012. Google Scholar2. Walensky RP, Sax PE, Nakamura YM, Weinstein MC, Pei PP, Freedberg KA, et al. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med. 2013;158:84-92. LinkGoogle Scholar3. Stoll M, Kollan C, Bergmann F, Bogner J, Faetkenheuer G, Fritzsche C, et al; ClinSurv Study Group. Calculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv cohort. PLoS One. 2011;6:23946. [PMID: 21931626] CrossrefMedlineGoogle Scholar4. Gazzard B, Moecklinghoff C, Hill A. New strategies for lowering the costs of antiretroviral treatment and care for people with HIV/AIDS in the United Kingdom. Clinicoecon Outcomes Res. 2012;4:193-200. [PMID: 22888265] MedlineGoogle Scholar5. Sloan CE, Champenois K, Choisy P, Losina E, Walensky RP, Schackman BR, et al; Cost-Effectiveness of Preventing AIDS Complications (CEPAC) investigators. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. AIDS. 2012;26:45-56. [PMID: 22008655] CrossrefMedlineGoogle Scholar6. Llibre JM, Arribas JR, Domingo P, Gatell JM, Lozano F, Santos JR, et al; Spanish Group for FDAC Evaluation. Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy. AIDS. 2011;25:1683-90. [PMID: 21673556] CrossrefMedlineGoogle Scholar7. Buscher A, Hartman C, Kallen MA, Giordano TP. Impact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, antiretroviral-naive HIV patients. Int J STD AIDS. 2012;23:351-5. [PMID: 22648890] CrossrefMedlineGoogle Scholar8. Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis. 2009;48:484-8. [PMID: 19140758] CrossrefMedlineGoogle Scholar9. Svicher V, Alteri C, Artese A, Forbici F, Santoro MM, Schols D, et al. Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. J Acquir Immune Defic Syndr. 2010;55:336-44. [PMID: 20739898] CrossrefMedlineGoogle Scholar10. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al; 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201. [PMID: 15249568] CrossrefMedlineGoogle Scholar11. Centers for Disease Control and Prevention (CDC). Vital signs: HIV prevention through care and treatment—United States. MMWR Morb Mortal Wkly Rep. 2011;60:1618-23. [PMID: 22129997] MedlineGoogle Scholar12. The White House Office of National AIDS Policy. National HIV/AIDS Strategy for the United States. Washington, DC: The White House Office of National AIDS Policy; 2010. Google Scholar13. Thompson MA, Mugavero MJ, Amico KR, Cargill VA, Chang LW, Gross R, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med. 2012;156:817-33. [PMID: 22393036] LinkGoogle Scholar14. Davey M. One-party control opens states to partisan rush. New York Times. 22 November 2012:A1. Google Scholar15. U.S. Department of Health and Human Services. Essential Health Benefits, Actuarial Value, and Accreditation Standards: Ensuring Meaningful, Affordable Coverage. Washington, DC: U.S. Department of Health and Human Services; 2012. Accessed at www.healthcare.gov/news/factsheets/2012/11/ehb11202012a.html on 2 December 2012. Google Scholar16. Martin EG, Schackman BR. What does U.S. health reform mean for HIV clinical care? J Acquir Immune Defic Syndr. 2012;60:72-6. [PMID: 22517415] CrossrefMedlineGoogle Scholar17. Sherer R. The future of HIV care in the USA. Sex Transm Infect. 2012;88:106-11. [PMID: 22158933] CrossrefMedlineGoogle Scholar18. Maxmen A. Generic HIV drugs will widen US treatment net. Nature. 2012;488:267. [PMID: 22895314] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Renslow Sherer, MDAffiliations: From University of Chicago, Chicago, Illinois.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M12-2981.Corresponding Author: Renslow Sherer, MD, Section of Infectious Diseases and Global Health, Department of Medicine, University of Chicago, 5841 South Maryland Avenue, MC5065, Chicago, IL 60637. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoEconomic Savings Versus Health Losses: The Cost-Effectiveness of Generic Antiretroviral Therapy in the United States Rochelle P. Walensky , Paul E. Sax , Yoriko M. Nakamura , Milton C. Weinstein , Pamela P. Pei , Kenneth A. Freedberg , A. David Paltiel , and Bruce R. Schackman Generic Antiretrovirals and HIV Care in the United States Jennifer Cohn Generic Antiretrovirals and HIV Care in the United States Renslow Sherer Metrics Cited byGeneric Antiretrovirals and HIV Care in the United StatesJennifer Cohn, MD, MPHGeneric antiretrovirals − a controversial option? 15 January 2013Volume 158, Issue 2 Page: 133-134 Keywords Antiretrovirals Drugs Forecasting HIV HIV prevention Infectious diseases Medicare Patient Protection and Affordable Care Act Toxicity Treatment guidelines ePublished: 15 January 2013 Issue Published: 15 January 2013 Copyright & PermissionsCopyright © 2013 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...